iO Resistant sqNSCLC

Clinical trial pipeline · Data from ClinicalTrials.gov

See which iO Resistant sqNSCLC trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT07217301

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Phase: 3 Type: Randomized, open-label, multi-regional, multi-center Population: Adults with advanced/metastatic squamous Non Small Cell Lung Cancer (NSCLC), pos…

United States600 participantsStarted 2025-11-26

Treatment: IBI363, Control Arm

iO Resistant sqNSCLC

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

All recent trials (1 shown)